Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive

• Status: Unknown status
• Trial end date: 2017-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of this study is to know the efficiency (costeffectiveness) at 48 weeks of initiation of antiretroviral treatment. three strategies of treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Juan A. Arnaiz
• Treatments: Abacavir; Cobicistat; Darunavir; Elvitegravir; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Lamivudine; Rilpivirine; Ritonavir; Tenofovir

Criteria

Inclusion Criteria:

• 1-negative pregnancy test in women of childbearing age

• 2- stable HIV-1 infection clinically and not take antiretroviral therapy

• 3- viral load HIV <100,000 copies

• 4- CD4 cells >100 cels/mm3

• 5- Glomerular filtration >70mlmin

• 6- have a negative HLA B5701

• 7-.patients should have given informed written consent

• 8- in the opinion of the investigator, be able to follow the design of the Protocol visits

Exclusion Criteria:

• 1-. Patients who had virologic failure with any antiretroviral therapy

• 2- evidence of prior mutations of the study drugs

• 3- use of any anti-retroviral treatment in the 6 months prior to the entry of the study

• 4- contraindication to the drugs study

• 5- any condition that does not allow to ensure the correct compliance to the study

• 6- uncontrolled previous psychiatric illness

• 7- Current or active addiction or alcoholism